| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -12.8 | -4.2 |
| Net income | -6.8 | -4.2 |
| EPS (diluted, $ a share) | $-0.73 | $-0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: LSTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lisata Therapeutics, Inc.: key numbers
- Share price
- $1.09Close, Nov 16
- Market cap
- $11.8M
- Shares outstanding
- 10.8MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lisata Therapeutics, Inc.
All →Lisata Therapeutics M&A Deal with Marea Therapeutics, Inc.
Lisata Therapeutics filed an amendment to its previous 8-K to provide required audited financial statements and pro forma financial information following its completed acquisition of Marea Therapeutics, Inc. The filing includes combined financial statements for Marea and M2 Therapeutics for the years 2024 and 2025, as well as interim 2026 data.
- Counterparty
- Marea Therapeutics, Inc.
Lisata Therapeutics Shareholder Meeting
Lisata Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders approved several key proposals. Most notably, stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 44.76 million shares and the 2026 Employee Stock Purchase Plan with an initial reserve of 3.73 million shares.
Lisata Therapeutics Leadership Change
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors as a Class III member and a member of the Audit Committee, effective October 13, 2026. The appointment expands the company's board from seven to eight members. Mr. Farrow is a veteran biopharmaceutical executive currently serving as CFO and Chief Strategy Officer of Tarsus Pharmaceuticals.
Lisata Therapeutics M&A Deal with Marea Therapeutics, Inc.
Lisata Therapeutics acquired Marea Therapeutics in an all-stock merger, resulting in Marea becoming a wholly owned subsidiary. Concurrent with the acquisition, Lisata secured $225 million in a private placement financing to fund the development of Marea's clinical-stage cardioendocrine pipeline through 2028. Following the transactions, former Marea equityholders and new PIPE investors hold the vast majority of the combined company's equity.
- Counterparty
- Marea Therapeutics, Inc.